<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Response criteria in acute myeloid leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Response criteria in acute myeloid leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Response criteria in acute myeloid leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Category</td> <td class="subtitle1">Definition</td> <td class="subtitle1">Comment</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Response</td> </tr> <tr> <td class="indent1">CR without minimal residual disease (CR<sub>MRD–</sub>)</td> <td>If studied pretreatment, CR with negativity for a genetic marker by RT–qPCR, or CR with negativity by MFC</td> <td>Sensitivities vary by marker tested, and by method used; therefore, test used and sensitivity of the assay should be reported; analyses should be done in experienced laboratories (centralized diagnostics)</td> </tr> <tr> <td class="indent1">Complete remission (CR)</td> <td>Bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 × 10<sup>9</sup>/L (1000/microL); platelet count ≥100 × 10<sup>9</sup>/L (100,000/microL)</td> <td>MRD<sup>+</sup> or unknown</td> </tr> <tr> <td class="indent1">CR with incomplete hematologic recovery (CR<sub>i</sub>)</td> <td>All CR criteria except for residual neutropenia (&lt;1.0 × 10<sup>9</sup>/L [1000/microL]) or thrombocytopenia (&lt;100 × 10<sup>9</sup>/L [100,000/microL])</td> <td> </td> </tr> <tr> <td class="indent1">Morphologic leukemia-free state (MLFS)</td> <td>Bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required</td> <td>Marrow should not merely be "aplastic"; at least 200 cells should be enumerated or cellularity should be at least 10%</td> </tr> <tr class="divider_bottom"> <td class="indent1">Partial remission (PR)</td> <td>All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%</td> <td>Especially important in the context of phase 1/2 clinical trials</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Treatment failure</td> </tr> <tr> <td class="indent1">Primary refractory disease</td> <td>No CR or CR<sub>i</sub> after 2 courses of intensive induction treatment; excluding patients with death in aplasia or death due to indeterminate cause</td> <td>Regimens containing higher doses of cytarabine are generally considered as the best option for patients not responding to a first cycle of 7+3; the likelihood of responding to such regimens is lower after failure of a first</td> </tr> <tr> <td class="indent1">Death in aplasia</td> <td>Deaths occurring ≥7 days following completion of initial treatment while cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 days of death, without evidence of persistent leukemia</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Death from indeterminate cause</td> <td>Deaths occurring before completion of therapy, or &lt;7 days following its completion; or deaths occurring ≥7 days following completion of initial therapy with no blasts in the blood, but no bone marrow examination available</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Response criteria for clinical trials only</td> </tr> <tr> <td class="indent1">Stable disease</td> <td>Absence of CR<sub>MRD–</sub>, CR, CR<sub>i</sub>, PR, MLFS; and criteria for PD not met</td> <td>Period of stable disease should last at least 3 months</td> </tr> <tr class="divider_bottom"> <td class="indent1">Progressive disease (PD)*<sup>¶</sup></td> <td>Evidence for an increase in bone marrow blast percentage and/or increase of absolute blast counts in the blood: <ul class="decimal_heading"> <li>&gt;50% increase in marrow blasts over baseline (a minimum 15% point increase is required in cases with &lt;30% blasts at baseline; or persistent marrow blast percentage of &gt;70% over at least 3 months; without at least a 100% improvement in ANC to an absolute level (&gt;0.5 × 10<sup>9</sup>/L [500/microL], and/or platelet count to &gt;50 × 10<sup>9</sup>/L [50,000/microL] nontransfused); or </li> <li>&gt;50% increase in peripheral blasts (WBC × % blasts) to &gt;25 × 10<sup>9</sup>/L (&gt;25,000/microL) (in the absence of differentiation syndrome)<sup>¶</sup>; or </li> <li>New extramedullary disease </li> </ul> </td> <td> <p>Category mainly applies for older patient given low-intensity or single-agent "targeted therapies" in clinical trials</p> <p>In general, at least 2 cycles of a novel agent should be administered</p> <p>Some protocols may require blast increase in 2 consecutive marrow assessments at least 4 weeks apart; the date of progression should then be defined as of the first observation date</p> <p>Some protocols may allow transient addition of hydroxyurea to lower blast counts</p> "Progressive disease" is usually accompanied by a decline in ANC and platelets and increased transfusion requirement and decline in performance status or increase in symptoms </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Relapse</td> </tr> <tr> <td class="indent1">Hematologic relapse (after CR<sub>MRD–</sub>, CR, CR<sub>i</sub>)</td> <td>Bone marrow blasts ≥5%; or reappearance of blasts in the blood; or development of extramedullary disease</td> <td> </td> </tr> <tr> <td class="indent1">Molecular relapse (after CR<sub>MRD–</sub>)</td> <td>If studied pretreatment, reoccurrence of MRD as assessed by RT–qPCR or by MFC</td> <td>Test applied, sensitivity of the assay, and cutoff values used must be reported; analyses should be done in experienced laboratories (centralized diagnostics)</td> </tr> </tbody></table></div><div class="graphic_footnotes">CR: complete response; MRD: measurable residual disease (also known as minimal residual disease); ANC: absolute neutrophil count; MLFS: morphologic leukemia-free state; WBC: white blood cell; IDH: isocitrate dehydrogenase; RT-qPCR: real-time quantitative polymerase chain reaction; MFC: multiparameter flow cytometry.<br/>* The authors acknowledge that this new provisional category is arbitrarily defined; the category aims at harmonizing the various definitions used in different clinical trials.<br/>¶ Certain targeted therapies, for example, those inhibiting mutant IDH proteins, may cause a differentiation syndrome, that is, a transient increase in the percentage of bone marrow blasts and an absolute increase in blood blasts; in the setting of therapy with such compounds, an increase in blasts may not necessarily indicate PD.</div><div class="graphic_reference">Reproduced with permission of the American Society of Hematology. From: Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424; permission conveyed through Copyright Clearance Center. Copyright © 2017.</div><div id="graphicVersion">Graphic 60024 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
